● GlobeNewsWireNov 16, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies…
Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Laura Prendergast - Stif…
● GlobeNewsWireNov 12, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Olema Oncology Announces Corporate Name Change
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discover…
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Target Price of $40.60
Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the company, MarketBeat.com repo…
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…
● GlobeNewsWireNov 3, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…
● GlobeNewsWireNov 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…
● Zacks Investment ResearchOct 16, 2026 · 10:46 ET
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.…
● GlobeNewsWireOct 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…
● GlobeNewsWireSep 2, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerciali…
● GlobeNewsWireAug 31, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercializ…
66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd.
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) during the second quarter, according to its most recent filing with the SEC. The firm bought 66,163 shares…
Article counts from the last market-wide feed page, across every symbol we track and not just OLMA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.